Traverse Biotech develops first-in-class immunotherapies from pre-clinical stage through clinical proof-of-concept in an original partnership model driving significant value for shareholders and maximizing patient benefit.

We identify cutting-edge immunology products from clinically validated platforms. We then develop these products in a novel risk-sharing model with our partners, bringing game-changing medicines to patients sooner. Our team has demonstrated preclinical, clinical, and on-market execution expertise enabling an efficient operational strategy. By leveraging technical capabilities, manufacturing capacity, and regulatory information from our partnership, Traverse is rapidly able to reach value-creating milestones, launching our products sooner to the patient.